RALEIGH, N.C., Aug. 23 /PRNewswire/ — PRA International,
a leading Clinical Research Organization, will exhibit our
cardiology expertise and experience at the European Society of
Cardiology’s (ESC) annual conference in Stockholm, Sweden from 28
August to 1 September 2010.
At PRA booth C18:62, attendees can schedule meetings with our
leading expert in cardiovascular (CV) disease, Dr. Michael
Kirchengast, Vice President and Head of Scientific Affairs at PRA,
to learn how PRA can support drug development projects.
In addition to his ESC attendance, Dr. Kirchengast is also
hosting a CV audio conference on 24 August 2010 at 11:30 am (EDT).
Those wishing to attend this session can learn key concepts
and explore new strategies for preventing some of the expensive
failures that pharmaceutical companies experience during late-stage
development.
Dr. Kirchengast has 30 years of experience in CV research and
development, including interactions with multiple authorities. His
wide range of development experience encompasses antiarrhythmics,
antithrombotics, antihypertensives, antihyperlipidemics, heart
failure therapeutics, and vascularly active and cardioprotective
drugs.
Additional PRA representatives, including Dr. Margit Banagl,
Executive Director of Medical Affairs, will be at ESC to provide
information on the full breadth of PRA’s services.
For more information about our ESC exhibit and Dr. Kirchengast’s
audio conference, navigate to www.praintl.com and click on
“Events.” To register for the audio conference, email
endpoints@praintl.com.
About PRA International
PRA International conducts clinical trials in more than 85
countries across 6 continents and provides services through all
phases of clinical development. PRA performs studies in all
therapeutic areas, with specialization in Oncology/Hematology
‘/>”/>
